Pharmaceuticals, Biotechnology and Life Sciences
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.
Allergan plc has confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction.
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana